Participants 50 148 8
advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
Participants 252 369 10
in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials.
Participants 695 966 5
Single agent or combination chemotherapy regimens including doxorubicin (A) (12%), doxorubicin/cisplatin (AP) (63%), doxorubicin/paclitaxel (AT) (13%), and paclitaxel/doxorubicin/cisplatin (TAP) (11%) were used among 1203 patients treated on 4 randomized clinical trials.
Participants 1140 1293 4
More S/CC patients enrolled on trials with advanced stage (III-IV) disease (as opposed to recurrent disease) compared to E patients (45% vs. 24%, p<0.05)
Participants 1681 1735 3
In patients with advanced/recurrent endometrial cancer
